Member Info for The_Paladin

Thank you Tyke. That is somewhat reassuring despite our current difficulties.

IB’s technology, and progress with the GliB trial are consistently presented so positively by the company.

I fail to understand that we have witnessed the erosion of the share price with no significant upward movement for well over two years? These two observations do not reconcile in any shape or form?

Is it just me or has there been attrition on the share price in a deliberate attempt to lower it? Should this be the case, presumably it is with a fund rise for further trialling in mind?

This would give the consistent 300K seller a golden opportunity to buy back at a significant premium when compared with the all time low 0.6p share price at which they sold their shares? Additionally, this would introduce further dilution adding to the increasing hurdle facing LTIs?

Each time I study the IB Wisconsin website, and the associated X feed, I see a company with vast potential due to the quality of its technology, and its involvement in what could be an important trial for GliB sufferers. Despite this we are treated to an increasingly worsening financial scenario without respite day by day, week by week. It is high time for this company to get a grip on monetising its USPs !

BB. “ I believe he was brought on for the FDA clearance and that is now - quite possibly - in doubt ....”

Correct me if I am wrong, but didn’t the FDA form a favourable impression of IB’s original BTD submission? Wasn’t if the case that they needed more background information before they could properly assess IB’s request?

Showjumper.

If you are desperate to offload your shares you could probably do so via the negotiated trade route, as is most likely the case for the daily 300K seller? It would probably also result in an all time low share price of 0.6p though?

Thank you Phil,

You are not rambling., but have suggested realistic fundraising scenarios for a Ph2 trial.

As stated yesterday, I was hopeful that IB would first focus on a resubmission to the FDA for BTD, but the RNS would suggest otherwise?

Your point about the fundraising issue might well prove to be pivotal in determining the future of IB, and our position as LTIs in the company. Hopefully not another investor death slide into oblivion? Having already experienced one of those in 2025, another would be difficult to accept.

Tyke,

“I believe in IB’s tech. I also trust MS and he has his and his team's reputation including his wife..”

So do I FWIW. This is why I have remained invested through thick and thin, and for several years.

Back to my previous conspiracy theory.

Dr Al Musella and Michael Schmainda, and his wife Prof. K. Schmainda are humanists - very decent and honourable people. This is obvious from my background reading about their immense contributions in providing support for GliB sufferers.

The same could be said about Prof. Sir Stephen Holgate, a founder, large shareholder, and director of Synairgen. A conversation with Prof. SSH at last year’s belated AGM led investors to believe that a significant investment, with investor participation, would lead to a Ph2 trial that could well restore Synairgen’s fortunes. What the good professor was oblivious to was that a scheme had already been devised, in which investors were invited to participate, but made it virtually impossible for them to buy in. The company subsequently delisted and an investment company is now running the show.

The fact that we have some wonderful human beings on board, as well as products with significant potential is no guarantee of future success. In Synairgen’s case, the same was true. However, in their case there were others lurking in the shadows, with their own agenda. The inclusion of long standing investors evidently was not a part of their plans.

Let us all hope that a very different scenario will play out for LTIs here. GLA.

Fair point Tyke. I find it difficult to believe that a serious investor, who had done their due diligence on the company, and its IP and other assets, would buy in at 1p, and sell at 4-5 months later at a 22-40% loss?

Previously, I didn’t want to believe what has been written about TEB’s transactions with his previous companies.

Unfortunately there could well be a parallel situation to Synairgen’s currently in play with IB? I won’t go into the details. They can be instantly summarised on ChatGPT, for anyone who is interested.

For TFG Holdings read BRH; there are parallels, but all this may be a perceived conspiracy theory on my part, based on my previous misfortune elsewhere?

IMO “games” are currently being played with this company’s share price. An informative though inconsequential RNS yesterday, closely followed by two 300K share sales - on consecutive days, and at an historically low share price for this company.

I am not usually into conspiracy theories, but there is a bad smell around this current abysmal situation! I just hope that I am wrong. After sitting through the collapse of Synairgen, mostly through the inaction and ineptitude of its pathetically poor CEO and leadership team, I hope that we do not suffer a similar fate here!

Thank you for that perfect description max. ChatGPT also provided some information (below), although I have failed to find an online reference to the term.

“Soft closing a clinical trial refers to a pause or partial shutdown of the trial without fully terminating or permanently stopping it. It's a more flexible and less final step than a "hard close" or official termination.

In detail:

When a trial is soft closed, it often means:

No new participants are being enrolled (enrollment is paused or stopped).

Ongoing participants may still be followed according to the protocol.

Data collection may continue for those already enrolled.

The study site or sponsor may be assessing next steps—like revising protocols, addressing safety or regulatory concerns, or waiting on interim data.

It's often done site-by-site in multi-center studies (e.g., one site may soft close while others remain open).

Common reasons for soft closing:

Interim analysis or review of preliminary results

Enrollment targets have been met

Safety concerns being investigated

Budgetary or logistical issues

Regulatory feedback or required amendments

In contrast:

Hard close: Full trial termination; no further activity, often due to safety issues, lack of efficacy, or business decisions.

Close-out: The formal end of the trial process, including database lock, final monitoring visits, and regulatory reporting.”

Have IB introduced a new phrase - ‘soft close’ - into trial jargon? I have just spent an interesting few minutes reminding myself of the phrases used in clinical trial descriptions. I haven’t seen the term ‘soft close’ used anywhere else? Lavatory seats and kitchen cabinet doors can be soft closing, but has this phrase been used elsewhere for clinical trials?

I view this morning’s update as a baby step in the right direction. IB can now analyse and update the existing data, presumably aiming at a resubmission to the FDA for BTD? The global incidence of GiB, while not being high is significant. IB are trialling a therapy aimed at improving the quality of life of sufferers from this terrible disease. Moreover, IB’s technology can enhance the quality of imaging, diagnosis, and patient treatment and care.

Sensible measures are needed from the company to bring the GaM treatment, and IB’s technology into mainstream use as soon as possible. Presumably this will be the primary focus, with no ulterior motive, of the company? I look forward to hearing about the next steps.

“Glioblastoma (GBM) is the most common and aggressive type of primary malignant brain tumor in adults, with an estimated 300,000 new cases diagnosed worldwide each year. While it's a relatively rare disease, with an incidence of 2-5 cases per 100,000 people in North America and Europe, it represents over 50% of all primary malignant brain tumors. The average survival time after diagnosis is typically 15 to 18 months, and less than 7% of patients survive past five years.”

A quick examination of yesterday’s trades makes it obvious that the share price shouldn’t have closed @ 0.625p yesterday. That is not the point though.

The company has had two USPs for several years, but has failed to demonstrate significant progress with either. Until IB demonstrates a considerable improvement in its product sales, or a significant development with the GaM Ph1 trial, we will continue to remain unnoticed and undervalued - except by disaffected sellers, as was the case yesterday. IB’s X and LinkedIn messages, and articles about the trial have not advanced our position.

The ball is in the company’s court. IB need to demonstrate that we are making reasonable progress, otherwise the share price will continue to diminish. I disagree with semantic, in that as the share price diminishes, so does our investment with it.

Earlier, I established that todays selling has been executed on a negotiated trade basis, hence the very low sale prices. My broker won't offer a price for selling 5000 shares, as has been the case for days. The company need to update the market with some positivity, otherwise disaffected holders will continue to dump their stock in a similar fashion. There are far better options out there for them to invest their capital.

Tyke. The IB (Wisconsin) website confirms that recruitment for the trial is continuing, and won't conclude until Dec 2025.

"The trial, being conducted at Froedtert & the Medical College of Wisconsin, is currently accepting participants and has an anticipated completion date of December 2025."

https://www.imagingbiometrics.com/clinical-trials/

I am awaiting news of the BTD re-submission to the FDA. IB may wait until the trial is concluded, and resubmit the full trial data with the requested enhanced information? Like everything associated with micro companies, with limited available funds, this is moving at a glacial pace.

Should our discussion on here be so much about TEB? I agree that his manoeuvres have severely affected the IQ-AI share price in recent years. We have not recovered; the recent company rebrand has had zero effect.

However this company is exclusively about IB (Wisconsin), its cutting edge tumour imaging technology including AI to bring about accurate diagnosis, as well as our involvement in a promising GaM trial.

TEB remains at the helm but for how much longer? Surely MS is not going to allow 20 years of hard work to be written off?

We are sorely in need of an update. This company’s share price has been in the doldrums for far too long.

GLA.

Jam96p.

Are you sure those four trades are buys? Going by the executed share price they might be 4 x £10K sales? The share price is holding up well though. It will be interesting to see what the day holds?

Interesting opinions on this board. We don’t all have to agree, and people who are often disparaged have been right - in the short term - on occasions. Their opinions are guesses based on their opinions or their research, as are mine and everyone else’s . If we knew what the future held, we would all be very wealthy.

The important factor for me is the long term outcome - perhaps in a few years? Meanwhile, should there be a surge, and I am able to sell out at a profit I may well take it? This is a high risk strategy, as it assumes buying back in at a lower price to make it worthwhile. One way or another, I intend remain invested, perhaps with some interim trading, for the long haul. The prospects are good, but having suffered a severe setback with one highly ramped and overrated investment, some scepticism remains. GLA.

Sorry. £0.00508, which is how my broker displays the share price in its transaction contracts.

Stan36.

You are right. I have just checked on my broker’s contract for that sale. The sell price was actually 0.00508p just before close of trading on Friday afternoon. I bought back too soon today. One of the difficulties with this share is FOMO. News can break at any time with a surge in buying, and an abrupt rise in the sp. This is why I was more than happy to settle for a 11% gain.

With regard to the 0.37p, didn’t I post that I was considering topping up when the share price was at that level? I didn’t, and regret it. I am still wary about over investing in a company as a consequence of the Synairgen collapse. As said earlier, I am hoping to claw some of that loss back with my Capai investment.

All the best to you.

I sold my entire holding at 0.507p last week, and bought back in this morning. The net result is that I have 11% more shares than before - for zero capital outlay. ( I should add that I also managed a successful trade yesterday, which added to my capital).

I would have had regrets had I missed out on a continued rise on Monday morning. However my “gamble” paid off. It was affordable as I was already well in profit.

I contemplated holding out for a further drop, but shortly decided that 11% was a significant increase to my holding. It wasn’t worth taking any further risk on this investment, which I would have bought back at a reduced number of shares had the rise continued.

Three years ago, I lost a huge amount of capital on an AIM company called Synairgen, which, as it turned out, was very poorly managed. They blew away a large sum collected during a placement to raise capital for a clinical trial. I am hoping that my investment here will contribute to recovering some of those losses. GLA.

BB.

I’m not sure. Hopefully, this century. It better come sooner rather than later though. Otherwise, it will be my descendants that will reap the possible benefit from my depleted investment. I note that our CEO turned 79 last month. It is also in his interest to ensure that the company’s plans are executed as quickly as possible.

Seriously though, I should have stated Q3/Q4 2025 earlier. My reasons are that the IB (Wisconsin) website informs us that the Ph1 trial is due to complete at the end of 2025. Also if the IB team are on point, and I suspect they are, they will have revised the BTD submission, and handed it to the FDA by then? I believe that it is a case of appending more detailed information to the original data? Their young team are probably working on it now?

Should that be granted, and we move into Ph2 of the trial, I expect that interested parties will start to ask questions? Things might then get interesting for us?

All IMHO. GLA.